{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:31:59Z","timestamp":1791941519071,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03071-w","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T07:23:05Z","timestamp":1735975385000},"page":"1196-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Costs of Oral Corticosteroid Use in Patients with Severe Asthma With\/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-5663","authenticated-orcid":false,"given":"Enrico","family":"Heffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1213-2989","authenticated-orcid":false,"given":"Pierluigi","family":"Paggiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2557","authenticated-orcid":false,"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"3071_CR1","unstructured":"Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. A GINA pocket guide for health professionals V3.0. 2021. https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/08\/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf. Accessed 18 Aug 2023."},{"key":"3071_CR2","doi-asserted-by":"publisher","first-page":"1700765","DOI":"10.1183\/13993003.00765-2017","volume":"50","author":"JM Foster","year":"2017","unstructured":"Foster JM, McDonald VM, Guo M, Reddel HK. \u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma. Eur Respir J. 2017;50:1700765.","journal-title":"Eur Respir J"},{"key":"3071_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/resp.13026","volume":"22","author":"C Porsbjerg","year":"2017","unstructured":"Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology. 2017;22:651\u201361.","journal-title":"Respirology"},{"key":"3071_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PW Hekking","year":"2015","unstructured":"Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896\u2013902.","journal-title":"J Allergy Clin Immunol"},{"key":"3071_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jaip.2014.05.005","volume":"2","author":"A von B\u00fclow","year":"2014","unstructured":"von B\u00fclow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2:759\u201367.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3071_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000338998","volume":"160","author":"S Accordini","year":"2013","unstructured":"Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160:93\u2013101.","journal-title":"Int Arch Allergy Immunol"},{"key":"3071_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/02770903.2014.906607","volume":"51","author":"PW Sullivan","year":"2014","unstructured":"Sullivan PW, Slejko JF, Ghushchyan VH, et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014;51:769\u201378.","journal-title":"J Asthma"},{"key":"3071_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"3071_CR9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","volume":"7","author":"E Heffler","year":"2019","unstructured":"Heffler E, Blasi F, Latorre M, et al. The Severe Asthma Network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7:1462\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3071_CR10","first-page":"45","volume":"9","author":"C Langdon","year":"2016","unstructured":"Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45\u201353.","journal-title":"J Asthma Allergy"},{"key":"3071_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105947","volume":"166","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166: 105947.","journal-title":"Respir Med"},{"key":"3071_CR12","unstructured":"Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. A GINA pocket guide for health professionals V2.0. 2019. https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/04\/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed 18 Aug 2023."},{"key":"3071_CR13","doi-asserted-by":"publisher","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","volume":"55","author":"F Holguin","year":"2020","unstructured":"Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline. Eur Respir J. 2020;55:1900588.","journal-title":"Eur Respir J"},{"key":"3071_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/resp.13730","volume":"25","author":"LP Chung","year":"2020","unstructured":"Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25:161\u201372.","journal-title":"Respirology"},{"key":"3071_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100464","volume":"13","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Blasi F, Paggiaro P, et al. Oral corticosteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2020;13: 100464.","journal-title":"World Allergy Organ J"},{"key":"3071_CR16","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.jaip.2018.04.008","volume":"6","author":"LE Barry","year":"2018","unstructured":"Barry LE, O\u2019Neill C, Patterson C, Sweeney J, Price D, Heaney LG. Age and sex associations with systemic corticosteroid-induced morbidity in asthma. J Allergy Clin Immunol Pract. 2018;6:2014-23.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3071_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"key":"3071_CR18","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","volume":"136","author":"P Lefebvre","year":"2015","unstructured":"Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136:1488\u201395.","journal-title":"J Allergy Clin Immunol"},{"key":"3071_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","volume":"71","author":"J Sweeney","year":"2016","unstructured":"Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71:339\u201346.","journal-title":"Thorax"},{"key":"3071_CR20","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52:1800703.","journal-title":"Eur Respir J"},{"key":"3071_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12931-017-0614-x","volume":"18","author":"LE Barry","year":"2017","unstructured":"Barry LE, Sweeney J, O\u2019Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18:129.","journal-title":"Respir Res"},{"key":"3071_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2018.03.018","volume":"138","author":"Z Zafari","year":"2018","unstructured":"Zafari Z, Sadatsafavi M, Chen W, FitzGerald JM. The projected economic and health burden of sub-optimal asthma control in Canada. Respir Med. 2018;138:7\u201312.","journal-title":"Respir Med"},{"key":"3071_CR23","doi-asserted-by":"crossref","unstructured":"Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev. 2020;29.","DOI":"10.1183\/16000617.0085-2019"},{"key":"3071_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2500\/aap.2016.37.4004","volume":"37","author":"VQ Nguyen","year":"2016","unstructured":"Nguyen VQ, Ulrik CS. Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma. Allergy Asthma Proc. 2016;37:125\u201339.","journal-title":"Allergy Asthma Proc"},{"key":"3071_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","volume":"203","author":"CM Suehs","year":"2021","unstructured":"Suehs CM, Menzies-Gow A, Price D, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A delphi study. Am J Respir Crit Care Med. 2021;203:871\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"3071_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12874-020-01065-0","volume":"20","author":"JM FitzGerald","year":"2020","unstructured":"FitzGerald JM, Tran TN, Alacqua M, et al. International Severe Asthma Registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20:212.","journal-title":"BMC Med Res Methodol"},{"key":"3071_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","volume":"76","author":"DJ Jackson","year":"2021","unstructured":"Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76:220\u20137.","journal-title":"Thorax"},{"key":"3071_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/all.13342","volume":"73","author":"S Maio","year":"2018","unstructured":"Maio S, Baldacci S, Bresciani M, et al. RItA: The Italian severe\/uncontrolled asthma registry. Allergy. 2018;73:683\u201395.","journal-title":"Allergy"},{"key":"3071_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","volume":"108","author":"F Schleich","year":"2014","unstructured":"Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723\u201332.","journal-title":"Respir Med"},{"key":"3071_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12948-017-0065-4","volume":"15","author":"G Senna","year":"2017","unstructured":"Senna G, Guerriero M, Paggiaro PL, et al. SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. Clin Mol Allergy. 2017;15:9.","journal-title":"Clin Mol Allergy"},{"key":"3071_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/thoraxjnl-2012-201869","volume":"67","author":"J Sweeney","year":"2012","unstructured":"Sweeney J, Brightling CE, Menzies-Gow A, Niven R, Patterson CC, Heaney LG. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax. 2012;67:754\u20136.","journal-title":"Thorax"},{"key":"3071_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2018.12.001","volume":"12","author":"GW Canonica","year":"2019","unstructured":"Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019;12: 100007.","journal-title":"World Allergy Organ J"},{"key":"3071_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","volume":"70","author":"S O'Neill","year":"2015","unstructured":"O\u2019Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70:376\u20138.","journal-title":"Thorax"},{"key":"3071_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.anai.2021.03.015","volume":"127","author":"J Reibman","year":"2021","unstructured":"Reibman J, Tan L, Ambrose C, et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127:318-25.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3071_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/thoraxjnl-2012-202093","volume":"67","author":"JR Smith","year":"2012","unstructured":"Smith JR, Noble MJ, Musgrave S, et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax. 2012;67:1052\u201360.","journal-title":"Thorax"},{"key":"3071_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76:543\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3071_CR37","first-page":"31","volume":"3","author":"PJ McDowell","year":"2021","unstructured":"McDowell PJ, Stone JH, Heaney LG. The role of quantification of glucocorticoid-associated toxicity in severe asthma. J Cell Immunol. 2021;3:31\u20135.","journal-title":"J Cell Immunol"},{"key":"3071_CR38","doi-asserted-by":"crossref","unstructured":"Giombi F, Pace GM, Pirola F, et al. Airways type-2 related disorders: multiorgan, systemic or syndemic disease? Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25020730"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03071-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:54:30Z","timestamp":1738407270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03071-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03071-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Enrico Heffler reports receiving grants and personal fees from Sanofi, Regeneron, AstraZeneca, Novartis, GlaxoSmithKline, Chiesi, Stallergenes-Greer, Almirall, Celltrion Healthcare, and Bosch. Francesco Blasi reports receiving grants and personal fees from AstraZeneca, Insmed, and Menarini, and personal fees from Chiesi, GlaxoSmithKline, Grifols, Om Pharma, Pfizer, Sanofi, Vertex, Viatris, and Zambon, all outside the submitted work. Pierluigi\u00a0Paggiaro received in the last 2 years personal grants for educational\u00a0activities from AstraZeneca, Chiesi, GSK, Guidotti and Sanofi,\u00a0and for participation\u00a0to advisory board from Chiesi and GSK. Giorgio Walter Canonica reports research or clinical trials grants paid to his Institution from Menarini, AstraZeneca,GSK, Sanofi Genzyme and fees for lectures oradvisory board participation from Menarini, AstraZeneca, Chiesi, Faes Farma, Firma, Genentech, Guidotti-Malesci, GSK, HAL Allergy, Innovacaremd, Novartis, OM Pharma, Red Maple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes, and Uriach Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The SANI registry study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All patients signed an informed consent. The collected data were anonymized (all identifiers have been irreversibly removed). The protocol was approved by the Central Ethics Committee (Comitato Etico Area Vasta Nord-Ovest Toscana; protocol number: study number 1245\/2016, protocol number: 73714) and all other centers\u2019 local ethics committees. The permission to access and use the data from the registry was granted by the registry owners.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}